Background:

Droxicainide is an antiarrhythmic agent.

In coronary artery occlusion study, Droxicainide reduces hypoperfused area that evolves to necrosis, and reduces the infarct size in dogs[1]. Droxicainide decreases the sinus node, atrial and ventricular excitability and contractile force and increases the refractoriness in the study of spontaneously beating atria, electrically stimulated atria and papillary muscles isolated from rats[2].

[1]. Faria DB, et al. Effects of lidocaine and droxicainide on myocardial necrosis: a comparative study. J Am Coll Cardiol. 1983 Jun;1(6):1447-52. [2]. Helgesen KG, et al. Comparison of electrophysiological and mechanical effects of droxicainide and lidocaine on heart muscle isolated from rats. Acta Pharmacol Toxicol (Copenh). 1984 Oct;55(4):303-7.